Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 4/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619785 | 1.00 | AKT1 (0.42) | AKT1SLC6A4SLC6A2CDK2NAMPT | |
| SCHEMBL4715527 | 0.87 | SMYD3 (0.46) | AKT1SLC6A4SLC6A2CDK2SLC6A3 | |
| SCHEMBL4715530 | 0.87 | SMYD3 (0.46) | AKT1SLC6A4SLC6A2CDK2SLC6A3 | |
| SCHEMBL5619214 | 0.80 | SLC6A2 (0.43) | SLC6A4SLC6A2SLC6A3AAK1 | |
| SCHEMBL5619219 | 0.80 | SLC6A2 (0.43) | SLC6A4SLC6A2SLC6A3AAK1 | |
| SCHEMBL4116055 | 0.79 | SMYD3 (0.53) | AKT1CDK2 | |
| SCHEMBL15719386 | 0.78 | SLC6A2 (0.45) | SLC6A4SLC6A2 | |
| SCHEMBL5618862 | 0.78 | KDM4D (0.41) | NAMPT | |
| SCHEMBL5618868 | 0.78 | KDM4D (0.41) | NAMPT | |
| SCHEMBL5619310 | 0.77 | CTSS (0.39) | RAB9AAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | DAIICHI PHARMACEUTICAL CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6762181-B1 | BROAD ANTIBACTERIAL ACTIVITY INCLUDING DRUG RESISTANT STAPHYLOCOCCUS AUREUS (MRSA), PNEUMOCOCCUS (PRSP) AND ENTEROCOCCUS (VRE); SAFELY USED IN CONJUCTION WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-13 | — | — | US | disclosed |
| EP-1182202-B1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI SEIYAKU CO (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1182202-A1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | Q6ZSR9, NAT1, NAT10 | AKT1 2395/4885SLC6A4 2252/4885SLC6A2 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.